medigraphic.com
ISSN 2992-779X (Digital)
ISSN 2007-6452 (Impreso)

2025, Número 2

<< Anterior Siguiente >>

Investigación en Discapacidad 2025; 11 (2)


Aspectos demográficos de pacientes con enfermedad de Parkinson en el Instituto Nacional de Rehabilitación ''Luis Guillermo Ibarra Ibarra'' en la Ciudad de México

Verduzco-Mendoza A, León-Hernández SR, Ávila-Luna AL, Bueno-Nava A, Olmos-Hernández AS, Gálvez-Rosas A

Idioma: Ingles.
Referencias bibliográficas: 50
Paginas: 44-50
Archivo PDF: 292.39 Kb.





REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jankovic J y Tan E. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020; 91 (8): 795-808.

  2. Kulcsarova K, Skorvanek M, Postuma RB, Berg D. Defining Parkinson's disease: past and future. J Parkinsons Dis. 2024; 14 (52): S257-S271.

  3. Giguére N, Burke Nanni S, Truseau L. On cell loss and selective vulnerability of neuronal populations in Parkinson's disease. Front Neurol. 2018; 19 (9): 455.

  4. Flores-Ponce X, Velasco I. Dopaminergic neuron metabolism: relevance for understanding Parkinson's disease. Metabolimics. 2024; 20 (6): 116.

  5. Luo Y. Qiao L, Li M, Wen X, Zhang W, Li X. Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci. 2024; 16: 1498756.

  6. Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson's disease. Lancet. 2024; 403 (10423): 283-292.

  7. Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018; 8 (s1): S3-S8.

  8. Kim D, Isidro-Pérez A, Doering M, Llibre-Rodriguez J, Acosta I, Rodriguez-Salgado A et al. Prevalence and Incidence of Parkinson's disease in Latin America: a meta-analysis. Mov Disord. 2024; 39 (1): 105-118.

  9. Elbaz A, Carcaillon L, Kab S, Moisan F. Epidemiology of Parkinson's disease. Rev Neurol. 2016; 172(1): 14-26.

  10. Kadastik-Eerme L, Taba N, Asser T, Taba P. The increasing prevalence of Parkinson's disease in Estonia. Acta Neurol Scand. 2018; 138 (3): 251-258.

  11. Lazaro-Figueroa A, Reyes-Pérez P, Morelos-Figaredo E, Guerra-Galicia C, Estrada-Bellman I, Salinas-Barboza K et al. MEX-PD: a national network for the epidemiological & genetic research of Parkinson's disease. MedRxiv. 2023; 23294700.

  12. Rodriguez-Violante M., Velásquez-Pérez L, Cervantes-Arriaga A. Incidence rate of Parkinson's disease in Mexico: analysis of 2014-2017 statistics. Rev Mex Neuroci. 2019; 20 (3): 136-140.

  13. Rodriguez-Violante M, Villar-Velarde A, Valencia-Ramos C, Cervantes-Arriaga A. Características epidemiológicas de pacientes con enfermedad de Parkinson de un hospital de referencia en México. Arch Neurocien 2011; 16 (2): 64-68.

  14. Cervantes-Arriaga A, Rodriguez-Violante M, López-Ruíz M, Estrada-Bellmann I, Zuñiga-Ramírez C, Otero-Cerdeira E et al. Caracterización de la enfermedad de Parkinson en México: Estudio ReMePark. Gac Med Mex 2013; 149: 497-501.

  15. Corona T, Cervantes-Arriaga A, Velasquez-Pérez L, Rodriguez-Violante M. Impact of a movement disorders clinic on the trends of Parkinson's disease consultations at a tertiary referral center. Rev Invest Clin. 2016; 68 (4): 176-180.

  16. Hoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. 1967. Neurology. 1998; 50 (2): 318.

  17. Martinez-Martin P, Skorvanek M, Rojo-Abuin J, Gregova Z, Stebbins G, Goetz C. Validation study of the hoehn and yahr scale included in the MDS-UPDRS. Mov Disord. 2018; 33(4): 651-652.

  18. Cerri S, Mus L, Blandini F. Parkinson's disease in women and men: what's the difference? Parkinsons Dis. 2019; 9 (3): 501-515.

  19. Patel R, Kompoliti K. Sex and gender differences in Parkinson's disease. Neurol Clin. 2023; 41 (2): 371-379.

  20. Vaidya B, Dhamija K, Guru P, Sharma SS. Parkinson's disease in women: Mechanisms underlying sex differences. Eur J Pharmacol. 2021; 895: 173862.

  21. Sullivan KL, Mortimer JA, Wang W, Zesiewicz TA, Brownlee HJ, Borestein AR. Occupational characteristics and patterns as risk factors for Parkinson's disease: a case control study. J Parkinson Dis. 2015; 5 (4): 813-820.

  22. Sieurin J, Andel R, Tillander A, Valdes EG, Pedersen NL, Wirdefeldt K. Occupational Stress and risk for Parkinson's disease: a nationwide cohort study. Mov Disord. 2018; 33 (9): 1456-1464.

  23. Najafi F, Mansournia MA, Abdollahpour I, Rohani M, Vahid F, Nedjat S. Association between socioeconomic status and Parkinson's disease: findings from a large incident case-control study. BMJ Neurol Open. 2023; 5 (1): e000386.

  24. Hoenig MC, Dzialas V, Banwinkler M, Asendorf A, Drzezga A, van Eimeren T. Educational level and its association with dopamine transporter loss in patients with Parkinson's disease. Parkinsonism Relat Disord. 2023; 115:105844.

  25. Martínez-Ramírez D, Rodríguez-Violante M, Velázquez-Ávila ES, Cervantes-Arriaga A, González-Cantú A, Corona T et al. Incidencia y distribución geográfica de la enfermedad de Parkinson en México. Salud Publica Mex. 2020; 62 (6): 873-875.

  26. Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: why is advancing age the biggest risk factor. Ageing Res Rev 2014; 14: 19-30.

  27. Rodriguez M, Rodriguez-Sabate C, Morales I, Sanchez A, Sabate M. Parkinson's disease as a result of aging. Aging Cell 2015; 14: 293-308.

  28. Maas B, Gottgens I, Tijsse Klasen H, Kapelle W, Radder D, Bloem B et al. Age and gender differences in non-motor symptoms in people with Parkinson's disease. Front Neurol. 2024; 15: 1339716.

  29. Collier T, Kanaan N, Kordower J. Aging and Parkinson's disease: different sides of the same coin? Mov Disord. 2017; 32 (7): 983-990.

  30. Trist B, Hare D, Double K. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. Aging Cell. 2019; 18 (6): e13031.

  31. Ma Y, Erb M, Moore D. Aging, cellular senescence and Parkinson's disease. J Parkinsons Dis. 2025; 15 (2): 239-254.

  32. Palmer J, Wilson N, Son S, Obrock P, Wrobel L, Rob M et al. Autophagy, aging, and age-related neurodegeneration. Neuron. 2025; 113 (1): 29-48.

  33. Goloubinoff P. Mechanisms of protein homeostasis in health, aging and disease. Swiss Med Wkly. 2016; 146: w14306.

  34. Calabrese V, Santoro A, Monti D, Crupi R, Di Paola R, Latteri S et al. Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free Radic Biol Med. 2018; 115: 80-91.

  35. Hong S, Page R, Truman P. Smoking, coffee intake, and Parkinson's disease: potential protective mechanisms and components. Neurotoxicology. 2025; 106: 48-63.

  36. Lehrer S, Rheinstein P. Constipation and cigarette smoking are independent influences for Parkinson's disease. Cureus. 2022; 14 (1): e21689.

  37. Jung S, Chun S, Cho E, Han K, Yoo J, Yeo Y et al. Changes in smoking, alcohol consumption, and the risk of Parkinson's disease. Front Aging Neurosci. 2023; 15: 1223310.

  38. Kim R, You D, Jung Y, Han K, Lee J. Sex differences in smoking, alcohol consumption, and risk of Parkinson's disease: a nationwide cohort study. Parkinsonism Relat Disord. 2020; 71: 60-65.

  39. Peng B, Yang Q, B Joshi R, Liun Y, Akbar M, Son B et al. Role of alcohol drinking in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Int J Mol Sci. 2020; 21 (7): 2316.

  40. Kim I, Yang T, Heath A, Simpson R, Reeves G, Green J et al. Role of alcohol drinking in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Mov Disord. 2020; 35(3): 443-449.

  41. Leite Silva A, Goncalves de Oliveira R, Diógenes G, de Castro Aguiar M, Sallem C, Lima M et al. Premotor, nonmotor and motor symptoms of Parkinson's disease: a new clinical state of the art. Ageing Res Rev. 2023; 84: 101834.

  42. Nielsen N, Skovbolling S. Non-motor symptoms in Parkinson's disease. Ugeskr Laeger. 2021; 183 (27): V01210089.

  43. Goldman J. Non-motor symptoms and treatments in Parkinson's disease. Neurol Clin. 2025; 43 (2): 291-317.

  44. Cattaneo C, Jost W. Pain in Parkinson's disease: pathophysiology, classification and treatment. J Integr Neurosci. 2023; 22 (5): 132.

  45. Buhmann C, Kassubek J, Jost W. Pain in Parkinson's disease: pathophysiology, classification and treatment. J Parkinsons Dis. 2020; 10 (s1): S37-S48.

  46. Tueth L, Duncan R. Musculoskeletal pain in Parkinson's disease: a narrative review. Neurodegener Dis Manag. 2021; 11 (5): 373-385.

  47. Kulievsky J. Pharmacological management of Parkinson's disease motor symptoms: update and recommendations from an expert. Rev Neurol. 2022; 75 (s04): S1-S10.

  48. Armstrong M, Okun M. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020; 323(6): 548-560.

  49. Ferraiolo M, Herman E. The complex molecular pharmacology of the dopamine D2 receptor: implications for pramipexole, ropinirole, and rotigotine. Pharmacol Ther. 2023; 245: 108392.

  50. Tripathi A, Gupta P, Bansal T. Management of psychiatric disorders in patients with Parkinson's diseases. Indian J Psichiatry. 2022; 64 (Suppl2): S330-S343.




2020     |     www.medigraphic.com